About Us | Contact Us |        

Improving Treatment Outcomes through Appropriate Pharmacotherapeutic Selection and Patient Assessment for Readiness to Change

Optimizing Treatment Selection for Opioid Use Disorder: Tailoring Mat Strategies to Improve Patient Outcomes
1 APA 1 AMA PRA Category 1 Credit(s)
Launch Date:
December 17, 2015
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Physicians, Physician Assistants, Nurse Practitioners, Psychiatrists

Relevant Terms:

Opioid use disorder (OUD)

Roger D. Weiss, MD, Chair

Roger D. Weiss, MD, Chair
Professor of Psychiatry
Harvard Medical School
Chief, Division of Alcohol and Drug Abuse
McLean Hospital
Belmont, MA

Dr. Weiss's career has focused on treatment and clinical research with substance-dependent patients. He has received numerous NIH grants developing integrated group therapy, an evidence-based treatment for co-occurring bipolar and substance use disorders; and leading a multi-site treatment study of prescription opioid dependence. He has authored over 300 publications, including several books, and was vice chair of the American Psychiatric Association Task Force on Practice Guidelines for Patients with Substance Use Disorders.
Dr. Weiss was named a member of honor by the Spanish Society for Dual Disorders in 2011; and has received numerous other awards, including the H. David Archibald Award for Outstanding Research and/or Practice in the Addictions from The Centre for Addiction and Mental Health in Toronto (2007), the Jack H. Mendelson Research Award from McLean Hospital (2012), and the Dan Anderson Research Award from the Hazelden Foundation (2012).

R. Kathryn McHugh, PhD

R. Kathryn McHugh, PhD
Assistant Professor, Department of Psychiatry
Harvard Medical School
Associate Psychologist
Division of Alcohol and Drug Abuse
McLean Hospital
Belmont, MA

Dr. R. Kathryn McHugh engages in a program of clinical and translational research focusing on the nature and treatment of anxiety and substance use disorders. She is particularly interested in the study of affective vulnerability factors, such as distress intolerance, that are common across psychological disorders, with a focus on those that can be modified with treatment. Additionally, Dr. McHugh conducts research on the dissemination and implementation of evidence-based treatments, with a particular focus on behavioral therapies.
Dr. McHugh is a recipient of awards from organizations such as the American Psychological Association and the College of Problems on Drug Dependence, and has received research funding from both local and national agencies, including a K23 Award from the National Institute on Drug Abuse. Dr. McHugh also specializes in cognitive behavioral therapy for depression, anxiety, and substance use disorders.

Charles P. O'Brien, MD, PhD

Charles P. O'Brien, MD, PhD
Kenneth Appel Professor
Department of Psychiatry
University of Pennsylvania
Philadelphia, PA

Dr. O'Brien received his MD and PhD degrees from Tulane University, and received residency training in psychiatry, neurology, and medicine at Harvard, the University of London, Tulane and the University of Pennsylvania (Penn). He is board-certified in psychiatry, neurology and addiction psychiatry.

One of the most prominent addiction researchers in the world, Dr. O'Brien has made many important discoveries and contributions over the past 30 years that have become the standard of care in addiction treatment throughout the world. Aside from developing medications to treat alcohol, opioid, and cocaine dependence, his work has also increased the understanding of the clinical aspects of addiction and the neurobiology of relapse.

Among his numerous honors, Dr. O'Brien was elected to the Institute of Medicine of the National Academy of Sciences in 1991, and received the Nathan B. Eddy award for research from the College on Problems of Drug Dependence in 2003. He has advised our national government on drug policy for decades, and was the President of the American College of Neuropsychopharmacology, and the Association for Research in Nervous and Mental Disease.

Dr. O'Brien is the Vice-Chair of Psychiatry at Penn, and the founding director of the prestigious Center for Studies of Addiction.
1. Describe the different agents that act on the mu opioid receptor in the brain-reward pathway, and how differences in their mechanism of action translate into clinical use
2. Review factors that facilitate or hinder adherence to opioid use disorder (OUD) treatment and assess patient readiness for changing behavior related to aberrant opioid use
3. Compare the efficacy, safety, and clinical rationale of the different FDA-approved pharmacotherapies for the treatment of OUD
4. Evaluate evidence-based treatment-matching strategies for OUD and approaches to overcoming barriers to treatment adherence

Statement of Need:             
Opioid use disorder (OUD) is a prevalent and serious psychiatric illness with severe consequences, including death, if left untreated. Despite the availability of evidence-based treatment guidelines and medications that aid in the withdrawal from opioids and in long-term maintenance, OUD continues to be underdiagnosed and undertreated. Recent studies indicate that clinicians treating OUD lack understanding about the mechanisms of action (MOAs) of available medications to treat OUD, and how medication choice can influence patient adherence to treatment and clinical outcomes. The scenarios that follow describe and illustrate patient and disease-related considerations in medication-assisted treatment of OUD.
Physician Accreditation Statement:               
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and HealthmattersCME. Global is accredited by the ACCME to provide continuing medical education (CME) for physicians.
Physician Credit Designation:           
Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Psychology Accreditation Statement:            
Global Education Group (Global) is approved by the American Psychological Association (APA) to sponsor continuing education for psychologists. Global maintains responsibility for this program and its content. This activity has been approved for a maximum of 1.0 CE credits for psychologists. The instructional level of this activity is intermediate.
Contact Information:           
For information about the accreditation of this program, please contact Global at 303-395-1782 or inquire@globaleducationgroup.com
Fee Information and Refund/Cancellation Policy:       
There is no fee for this educational activity.
Disclosure of Conflicts of Interest:
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient-care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Roger D. Weiss, MD, Chair
Consultant/Independent Contractor: Reckitt Benckiser Scientific Advisory Board
R. Kathryn McHugh, PhD                           
Nothing to disclose
Charles P. O’Brien, MD, PhD             
Consultant/Independent Contractor: Embera NeuroTherapeutics, Inc., and Alkermes
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Name of Planner or Manager   Reported Financial Relationship
Andrea Funk  Nothing to disclose
Amanda Glazar, PhD  Nothing to disclose
James Murphy  Nothing to disclose
Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and HealthmattersCME do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions for Receiving Credit:
In order to receive credit for this activity, the participant must review the content, complete the post-test with a passing score of 70% or higher, and complete the evaluation form.
This activity is jointly provided by Global Education Group and HealthmattersCME.
This activity is supported by an independent educational grant from Alkermes.
Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above